

North Central Cancer Treatment Group

N0272 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) In Treatment of
Recurrent Oligodendroglioma and Mixed Oligoastrocytoma

Status Change – October 27, 2006

NOTICE OF STATUS CHANGE

Study 1, Arm C (EIAC's patients) will re-open for the accrual of 3 additional patients at dose level 1 effective October 27, 2006. IRB approval of Addendum 5 will be required before any new patient accrual.

Please retain this notice with the protocol.